Tiziana Life Sciences PLC Issue of Equity and Directorate Change (9687T)
20 Noviembre 2019 - 1:00AM
UK Regulatory
TIDMTILS
RNS Number : 9687T
Tiziana Life Sciences PLC
20 November 2019
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Issue of equity and directorate change
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
New York/London, 20 November 2019 - Tiziana Life Sciences plc
(Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the
discovery and development of innovative therapeutics for
inflammation and oncology indications, announces that it has issued
190,698 ordinary shares of 3p each ("Ordinary Shares") credited as
fully paid at a price of 43p per share in satisfaction of a
consultancy fee of GBP82,000. The Company also announces that
Leopoldo Zambeletti has resigned as a director of the Company.
Issue of Equity
The Company has today issued 190,698 ordinary shares of 3p each
("Ordinary Shares") credited as fully paid at a price of 43p per
share in satisfaction of a consultancy fee of GBP82,000.
Application will be made to the London Stock Exchange to admit
the 190,698 new Ordinary Shares to trading on AIM. Admission of the
new Ordinary Shares is expected to occur on or around 26 November
2019 ("Admission"). The new Ordinary Shares will rank pari passu
with the existing Ordinary Shares.
Following Admission, the issued share capital of the Company
will be 136,654,516 Ordinary Shares and this figure may be used by
shareholders as a denominator for the calculations by which they
will determine if they are required to notify their interest in, or
change to their interest, the Company, under the Disclosure
Guidance and Transparency Rules published by the UK Financial
Conduct Authority. There are no Ordinary Shares held in treasury.
Each Ordinary Share entitles the holder to a single vote at general
meetings of the Company.
Directorate Change
The Company also announces that Leopoldo Zambeletti has tendered
his resignation as a non-executive officer of the Company. The
Company notes the significant business interests of Mr Zambeletti
in a wide range of life sciences companies and expresses its
gratitude for Mr Zambeletti's contribution to the Company during
his tenure.
The person who arranged for release of this announcement on
behalf of the Company was Tiziano Lazzaretti, Chief Financial
Officer of Tiziana.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
milciclib, the Company is also developing foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody known to the company in clinical development in the world.
This compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as non-alcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBS),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
inflammatory bowel disease (IBD), psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
For further enquiries:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser) +44 (0)20 7213 0883
Liam Murray / Jo Turner
Shore Capital (Broker) +44 (0)20 7408 4050
Antonio Bossi / Fiona Conroy
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGGMWGUPBGMB
(END) Dow Jones Newswires
November 20, 2019 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Tiziana Life Sciences (LSE:TILS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024